Markets:

Overview

News

Currencies

International

Treasuries

Sight Sciences, Inc. - Common Stock (NQ:SGHT)

6.470 -0.130 (-1.97%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sight Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Sight Sciences' TearCare Surpasses Restasis Dry Eye Treatment, Trial Data shows ↗

July 20, 2023

Sight Sciences Inc (NASDAQ: SGHT) released the six-month SAHARA randomized controlled trial comparing interventional eyelid procedures enabled by TearCare Technology to Restasis

Via Benzinga

Glaukos Poised To Surpass Expectations And Raise Outlook In Q2 FY23, Fueled By iStent And iAccess Launches: Analyst ↗

July 19, 2023

Needham expects Glaukos Corp (NYSE: GKOS) to surpass expectations and raise outlook in Q2 FY23, fueled by rebounding iStent inject volumes post-2022 reimbursement-driven declines. An additional upside...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2023 ↗

July 11, 2023

Via Benzinga

Recap: Sight Sciences Q1 Earnings ↗

May 04, 2023

Via Benzinga

A Preview Of Sight Sciences's Earnings ↗

March 10, 2023

Via Benzinga

Earnings Scheduled For August 3, 2023 ↗

August 03, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.

Via Benzinga

Why Metropolitan Bank Holding Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

July 21, 2023

Gainers Digital World Acquisition Corp. (NASDAQ: DWAC) jumped 69% to $22.59 after the company announced it reached a settlement with the SEC.

Via Benzinga

Scholastic, Matson, Digital World Acquisition And Other Big Stocks Moving Higher On Friday ↗

July 21, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 90 points on Friday. Here are some big stocks recording gains in today’s session. Digital World Acquisition Corp. (NASDAQ: DWAC) climbed 69%...

Via Benzinga

Analyst Expectations for Sight Sciences's Future ↗

July 11, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 10, 2023 ↗

July 10, 2023

Via Benzinga

BlackRock To Rally Around 22%? Here Are 10 Other Analyst Forecasts For Monday ↗

July 10, 2023

Keybanc raised the price target for BILL Holdings, Inc. (NYSE: BILL) from $110 to $140. Keybanc analyst Josh Beck maintained an Overweight rating. BILL Holdings shares fell 2.3% to $113.00 in...

Via Benzinga

Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy)

June 21, 2023

From Sight Sciences, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

June 02, 2023

Via Benzinga

Why Guidewire Software Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

June 02, 2023

Gainers MultiMetaVerse Holdings Limited (NASDAQ: MMV) gained 236% to $3.1592 after the company announced it signed a non-binding term sheet to acquire an equity stake in Taomee group.

Via Benzinga

Sight Sciences' Cataract Surgery Tech Shows Consistent Lowering Of Eye Pressure, Medication Use ↗

May 23, 2023

Sight Sciences Inc (NASDAQ: SGHT) published two-year results of the so-called "Romeo" study of the OMNI Surgical System.

Via Benzinga

Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical

May 23, 2023

From Sight Sciences, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 08, 2023

Via Benzinga

Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry

May 06, 2023

Patients undergoing procedures enabled with OMNI® Surgical System technology experienced a greater average reduction in IOP-lowering medication usage compared to other MIGS procedures or cataract...

From Sight Sciences, Inc.

Via GlobeNewswire

Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023

May 04, 2023

From Sight Sciences, Inc.

Via GlobeNewswire

Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

May 01, 2023

Clinical data includes long-term trial results and robust real-world comparative data from IRIS® Registry

From Sight Sciences, Inc.

Via GlobeNewswire

Sight Sciences to Present at the Upcoming Bank of America Securities 2023 Health Care Conference

April 26, 2023

From Sight Sciences, Inc.

Via GlobeNewswire

Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023

April 20, 2023

From Sight Sciences, Inc.

Via GlobeNewswire

Sight Sciences to Host Surgical Glaucoma Investor Symposium on Friday, May 5, 2023

April 13, 2023

The event will include presentations from leading glaucoma surgeons and remarks from the Sight Sciences executive management team

From Sight Sciences, Inc.

Via GlobeNewswire

Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

April 03, 2023

From Sight Sciences, Inc.

Via GlobeNewswire

Sight Sciences Defeats Invalidity Challenges Filed By Alcon and Ivantis In The U.S. Patent Office

March 30, 2023

From Sight Sciences, Inc.

Via GlobeNewswire

Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results

March 13, 2023

From Sight Sciences, Inc.

Via GlobeNewswire

Sight Sciences Launches the Ergo-Series of the OMNI® Surgical System

March 09, 2023

The Ergo-Series maximizes ergonomics and surgical ease-of-use while continuing to enable surgeons to perform minimally invasive, implant-free glaucoma procedures

From Sight Sciences, Inc.

Via GlobeNewswire

Glaucoma Is The Second Leading Cause Of Blindness Globally – Skye Bioscience Appears To Be Making Rapid Progress In The Development Of Their Candidate To Treat It ↗

March 09, 2023

Biomed company Skye Bioscience (OTCQB: SKYE) has seen positive results in its clinical research so far and is preparing for the next stage in the development of its therapy for eye disease.

Via Benzinga

Sight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023

February 23, 2023

From Sight Sciences, Inc.

Via GlobeNewswire

Sight Sciences to Present at the Upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference

February 22, 2023

From Sight Sciences, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.